Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1021
-
1022
-
1023
-
1024
-
1025
Decrease of NF-κB activity in tumor tissue of CCR5<sup>−/−</sup> mice.
Published 2013“…<p><b>A</b>, The DNA binding activity of NF-κB was determined in the nuclear extracts of the CCR5<sup>−/−</sup> mice and CCR5<sup>+/+</sup> mice tumor tissues by EMSA described in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0033747#s4" target="_blank">material and methods</a>. …”
-
1026
PEGylated pUR4/FUD peptide inhibitor of fibronectin fibrillogenesis decreases fibrosis in murine Unilateral Ureteral Obstruction model of kidney disease
Published 2018“…Decreased fibronectin was accompanied by a decrease in collagen and leukocyte infiltration. …”
-
1027
-
1028
-
1029
-
1030
Inflammatory Adipokines Decrease Expression of Two High Molecular Weight Isoforms of Tropomyosin Similar to the Change in Type 2 Diabetic Patients
Published 2016“…The change in expression in HMW isoforms from TPM1 and TPM4 was replicated in THP1 cells treated with 1 ng/ml TNFα (0.10 and 0.12 v 1.00 respectively) or 10 ng/ml IL-1α (0.17 and 0.14 v 1.00 respectively). …”
-
1031
-
1032
-
1033
-
1034
-
1035
-
1036
-
1037
AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial
Published 2018“…AZP-531, a first-in-class UAG analog, was shown to inhibit the orexigenic effect of AG in animals, to improve glycemic control and decrease body weight in humans. We aimed to investigate the safety and efficacy of AZP-531 in patients with PWS for whom no approved treatment for hyperphagia is currently available.…”
-
1038
-
1039
-
1040